Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial
Journal of the Pediatric Infectious Diseases Society · 2024
DOI: 10.1093/jpids/piae076 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2024. Verfasst von Hylke Waalewijn und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Pyridones, Heterocyclic Compounds, 3-Ring, Oxazines, Piperazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European and Developing Countries Clinical Trials Partnership, Janssen Pharmaceuticals and Gilead Sciences Inc, NIAID NIH HHS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
We characterized population pharmacokinetics in 42 African children receiving once-daily 25 mg (14 to <20 kg) or 50 mg (>20 kg) dolutegravir. Coadministration with emtricitabine and tenofovir alafenamide reduced dolutegravir bioavailability by 19.6% (95% confidence interval: 8.13%–30.8%) compared with zidovudine or abacavir with lamivudine. Nevertheless, concentrations remained above efficacy targets, confirming current dosing recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
- Medical Research Council Clinical Trials Unit, University College London, London, UK.
- Infection, Immunity & Inflammation Department, UCL Great Ormond Street Hospital Institute of Child Health, London, UK.
- Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
ORCID-Profile: Roeland E Wasmann, Helen M McIlleron, Angela Colbers, Paolo Denti
Förderung
- European and Developing Countries Clinical Trials Partnership
- Janssen Pharmaceuticals and Gilead Sciences Inc
- NIAID NIH HHS
- South African National Institute of Allergy and Infectious Diseases (NIAID) of the South African National Institutes of Health
Zitieren
APA
Waalewijn, H., Wasmann, R. E., Bamford, A., Gibb, D. M., McIlleron, H. M., Colbers, A., Burger, D. M., Denti, P., & CHAPAS-4 trial team (2024). Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piae076
Vancouver
Waalewijn H, Wasmann RE, Bamford A, Gibb DM, McIlleron HM, Colbers A, et al. Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial. Journal of the Pediatric Infectious Diseases Society. 2024. doi:10.1093/jpids/piae076
BibTeX
@article{Waalewijn2024,
author = {Waalewijn, Hylke and Wasmann, Roeland E and Bamford, Alasdair and Gibb, Diana M and McIlleron, Helen M and Colbers, Angela and Burger, David M and Denti, Paolo and CHAPAS-4 trial team, CHAPAS-4 trial team},
title = {Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial},
journal = {Journal of the Pediatric Infectious Diseases Society},
year = {2024},
doi = {10.1093/jpids/piae076}
}
EUVIMED